drugset / Trial / NCT05329168
ERAdicate S. Aureus in Patients With Bacteremia and Endocarditis
NaSingle-groupOpen-labelTreatment
Summary
This study evaluates safety and tolerability of endolysin-derived LSVT-1701 (tonabacase) as an add-on to standard of care (SOC) antibiotic therapy for the treatment of patients with complicated Staphylococcus aureus bacteremia (SAB), including left- and right-sided infective endocarditis (IE).
Timeline
- Start
- 2022-05-01
- Primary completion
- 2023-08-17
- Completion
- 2023-11-01
Outcome
Outcome not reported
Stopped (Business): “business decision before FPFV; not related to any safety concerns”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tonabacase | Protein / enzyme biologic | 4.5 mg/kg | Intravenous |
| Subject | Tonabacase | Protein / enzyme biologic | 6 mg/kg | Intravenous |